Cutaneous Inflammation and Proliferation in vitro: Differential Effects and Mode of Action of Topical Glucocorticoids

  title={Cutaneous Inflammation and Proliferation in vitro: Differential Effects and Mode of Action of Topical Glucocorticoids},
  author={Katharina Lange and Burkhard Kleuser and Anja Gysler and Michael Bader and Cl{\'a}udia de Castro Rizzi Maia and Claus Scheidereit and Hans Christian Korting and Monika Sch{\"a}fer-Korting},
  journal={Skin Pharmacology and Physiology},
  pages={93 - 103}
The nonhalogenated double ester of prednisolone, prednicarbate (PC), is the first topical glucocorticoid with an improved benefit/risk ratio verified clinically and in vitro. To evaluate if this is due to unique characteristics of this steroid, a new compound created according to an identical concept, prednisolone 17-ethylcarbonate, 21-phenylacetate (PEP), and the new halogenated monoester desoximetasone 21-cinnamate (DCE) were tested and compared to PC, desoximetasone (DM) and betamethasone 17… 

Figures and Tables from this paper

Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model.
Qualitative and Quantitative Assessment of the Benefit-Risk Ratio of Medium Potency Topical Corticosteroids In Vitro and In Vivo
A new approach to in vitro quantification of the benefit-risk ratio has been developed, and drugs that selectively modulate cytokine release appear to be equipotent alternatives to the gold standard betamethasone 17-valerate with respect to anti-inflammatory activity.
Evaluation of Anti-inflammatory and Atrophogenic Effects of Glucocorticoids on Reconstructed Human Skin a
Initial studies with fibroblasts and keratinocytes confirmed the anti-inflammatory and atrophogenic effects of GCs, as evidenced by decreased cytokine production and collagen mRNA expression, and reproducible epidermal inflammation was established for the first time in reconstructed human skin.
New and Established Topical Corticosteroids in Dermatology
The new molecules, compared with the well known and established corticosteroids, generally have a higher anti-inflammatory effect, good compliance among patients (only a once-daily application is needed), rarely induce cross-sensitivity reactions and have weak atrophogenicity.
Glucocorticoids for Human Skin: New Aspects of the Mechanism of Action
The extended knowledge of glucocorticoid-induced cellular signalling should allow the design and development of even more specifically acting drugs – as it has been obtained with other steroids, e.g. estrogens for osteoporosis prevention.
Investigations of in vitro test systems for the detection of Glucocorticoid-induced skin atrophy as a tool in drug discovery
A cascade of three in vitro models based on NHEK, 3T3 fibroblasts and FTSM is recommended to be applied for the characterization of the atrophogenicity of GC receptor ligands and the predictability of these models for the clinical situation is analyzed.
Prednicarbate (Dermatop®): Profile of a Corticosteroid
Prednicarbate is a nonhalogenated, double-ester derivative of prednisolone that has been used in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses such as atopic dermatitis and has a favorable benefit–risk ratio, low skin atrophy potential, and high anti-inflammatory action.
Glucocorticoids mediate differential anti‐apoptotic effects in human fibroblasts and keratinocytes via sphingosine‐1‐phosphate formation
It was revealed that growth inhibitory concentrations of this glucocorticoid did not induce fibroblast apoptosis, and DEX protected these cells from apoptosis induced by tumor necrosis factor α/actinomycin, UV‐irradiation, and cell permeable ceramides.
Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy
Clinical and preclinical data support the value of fixed-dose combination therapy of corticosteroid and vitamin D analog and highlight the added potential of innovative drug delivery for the treatment of psoriasis.


Topical Glucocorticoids with Improved Risk-Benefit Ratio
Qualitative and quantitative assessment of the therapeutic and adverse effects of non-halogenated double-ester-type glucocorticoids suggests an increased benefit-to-risk ratio.
Cytokine inhibition by a novel steroid, mometasone furoate.
The inhibition of the production of proinflammatory mediators by extremely low concentrations of mometasone furoate suggests that this steroid should be highly effective in various disorders.
The interleukin-1 axis and cutaneous inflammation.
Transgenic mice that overexpress each of these factors individually in epidermis will be useful for enhancing the understanding of the cutaneous biology of IL-1.
Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids
It is shown that the synthetic glucocorticoid dexamethasone induces the transcription of the IκBα gene, which results in an increased rate of Iκbα protein synthesis, which is predicted to markedly decrease cytokine secretion and thus effectively block the activation of the immune system.
Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis
It is shown that glucocorticoids are potent inhibitors of nuclear factor kappa B activation in mice and cultured cells, mediated by induction of the IκBα inhibitory protein, which traps activated NF-κB in inactive cytoplasmic complexes.
Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Inhibition of UV-B-induced inflammation monitored by laser Doppler blood flowmetry.
  • P. Bjerring
  • Medicine, Chemistry
    Skin pharmacology : the official journal of the Skin Pharmacology Society
  • 1993
The bioactivity of a novel topical glucocorticosteroid was compared with betamethasone dipropionate 0.05% cream and betametasone valerate 0.1% cream, and laser Doppler blood flowmetry showed that mometasone furoate 1% fatty cream was more than twofold better in reducing UV-B-induced inflammation.
Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids
Nonhalogenated double esters of prednisolone or hydrocortisone applied topically to the skin have a low atrophogenic potential. However, activity and benefit/risk ratio and therefore the superiority